LOS ANGELES, April 2026

Adagio Medical announced positive pivotal clinical results for its vCLAS® Ventricular Ablation System, highlighting a major advancement in the treatment of ventricular tachycardia (VT). The findings, presented at a leading scientific forum, demonstrate the system’s ability to deliver effective, durable lesion formation with a favorable safety profile, reinforcing its potential to transform treatment strategies for patients with complex cardiac arrhythmias.

Strong Clinical Outcomes in Ventricular Tachycardia Treatment

The pivotal study evaluated the efficacy and safety of the vCLAS system in patients with drug-refractory ventricular tachycardia, a life-threatening condition often associated with structural heart disease. Results showed that the system achieved high procedural success rates, with significant reduction in VT episodes post-treatment. Importantly, patients treated with vCLAS experienced durable arrhythmia control, suggesting that the technology may overcome limitations of conventional thermal ablation techniques.

The system’s novel ultra-low temperature cryoablation technology enables deeper and more consistent lesion formation, targeting arrhythmogenic tissue more precisely. This approach is particularly beneficial in VT, where complex substrates and deep myocardial circuits often challenge traditional ablation modalities. The study further demonstrated that the technology supports efficient procedural workflows, potentially reducing procedure time and improving overall clinical outcomes.

Innovative Technology Driving Precision and Safety

Advertisement

cGxPJobs Banner

At the core of the vCLAS system is Adagio Medical’s proprietary cryoablation platform, designed to deliver ultra-low temperatures that enhance tissue penetration while minimizing collateral damage. Unlike radiofrequency-based systems, this technology provides uniform lesion geometry, improving the likelihood of complete arrhythmia pathway disruption.

Safety outcomes from the trial were encouraging, with low rates of procedure-related complications and no unexpected adverse events reported. The system’s design allows clinicians to maintain control and precision during ablation, which is critical when treating high-risk cardiac patients. These findings underscore the clinical reliability and safety profile of the vCLAS system, positioning it as a promising alternative in electrophysiology practice.

Implications for Future Cardiac Care

Ventricular tachycardia remains a significant clinical challenge, particularly in patients who do not respond to antiarrhythmic medications or prior ablation therapies. The positive results from Adagio Medical’s pivotal study highlight the potential for next-generation ablation technologies to address unmet needs in this space.

By enabling more effective targeting of arrhythmogenic tissue, the vCLAS system may improve long-term patient outcomes, reduce recurrence rates, and decrease reliance on repeat procedures. Additionally, the technology aligns with broader healthcare goals of enhancing precision medicine and improving procedural efficiency.

Adagio Medical’s continued innovation reflects a commitment to advancing cardiac electrophysiology through cutting-edge technology and rigorous clinical validation. As the company progresses toward regulatory engagement and potential commercialization, the vCLAS system could play a key role in redefining the standard of care for ventricular tachycardia treatment.

The study’s findings also support ongoing research into expanded applications of cryoablation technology, potentially extending its use across a broader range of cardiac arrhythmias. With increasing demand for safe, effective, and minimally invasive treatment options, technologies like vCLAS are poised to make a meaningful impact on patient care and clinical practice worldwide.

Source: Adagio Medical press release